Peptides for women, ranked by human evidence

The peptides with real human evidence for women are prescription drugs: GLP-1 drugs such as tirzepatide and semaglutide for weight, teriparatide and abaloparatide for osteoporosis, and bremelanotide, sold as Vyleesi and often searched as PT-141, for low sexual desire. Beyond those, the evidence thins quickly. Kisspeptin is a research tool, and the skin peptide GHK-Cu rests on small topical studies.

This list ranks the peptides women most often ask about by our evidence grades, with legal status for each. It is not a substitute for a clinician who knows your history, especially if you are pregnant, planning a pregnancy, or breastfeeding.

How we ranked peptides for women

We ordered the list by three criteria, in this order:

1. Evidence grade. Human randomized trials first, then observational human data. Grades come from each peptide's record.
2. Lawful access. Within a grade, an approved drug for a women's condition ranks above an approved drug used off-label, which ranks above one with no lawful route.
3. How directly the trials studied women. A trial enrolling only women with the condition ranks above a mixed or indirect one.

Statuses and prices were verified on September 22, 2026.

The ranking at a glance

• Approved, human trials in women: 1 tirzepatide and semaglutide, 2 teriparatide, 3 abaloparatide, 4 bremelanotide (PT-141), 5 calcitonin.
• Approved, weak evidence for the popular use: 6 oxytocin.
• Observational human data: 7 gonadorelin, 8 kisspeptin-10, 9 GHK-Cu.

1. Tirzepatide and semaglutide (GLP-1 drugs)

• GradeEvidence: Human RCT
• StatusRegulatory: FDA approved
• WADAWADA: Not prohibited

For weight, tirzepatide and semaglutide have the largest trials of any peptides. In SURMOUNT-1, adults on the highest tirzepatide dose lost a mean 20.9% of body weight over 72 weeks versus 3.1% on placebo. [1] In STEP 1, semaglutide produced a mean 14.9% loss over 68 weeks versus 2.4%. [2]

Two label details matter specifically for women. Tirzepatide can reduce the effect of oral hormonal contraceptives, so its label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase. [3] The Wegovy label advises stopping semaglutide at least 2 months before a planned pregnancy because it takes a long time to clear the body. [4] Compare them on semaglutide vs tirzepatide, and see every weight option on our weight loss ranking and obesity page.

2. Teriparatide (Forteo)

• GradeEvidence: Human RCT
• StatusRegulatory: FDA approved
• WADAWADA: Not prohibited

Teriparatide is the active part of parathyroid hormone, and it builds new bone. In a trial of 1,637 postmenopausal women with prior spine fractures, new vertebral fractures occurred in 5% on the approved daily dose versus 14% on placebo. [5] In VERO, 1,360 women with severe osteoporosis had new vertebral fractures in 5.4% on teriparatide versus 12.0% on risedronate, an oral osteoporosis drug. [6] It is approved for postmenopausal women with osteoporosis at high risk of fracture, among other groups. [7]

The brand pen, a 28-day supply, had a manufacturer list price of 4,289.89 USD as of September 22, 2026, and generic versions cost less. [8] See the teriparatide cost page and our osteoporosis page.

3. Abaloparatide (Tymlos)

• GradeEvidence: Human RCT
• StatusRegulatory: FDA approved
• WADAWADA: Not prohibited

Abaloparatide is an analog of parathyroid hormone related protein. In ACTIVE, 2,463 postmenopausal women with osteoporosis were randomized for 18 months; new vertebral fractures occurred in 0.58% on abaloparatide, 4.22% on placebo, and 0.84% on open-label teriparatide. [9] It is approved for postmenopausal women with osteoporosis at high risk of fracture. [10] For the head-to-head details, see teriparatide vs abaloparatide.

4. Bremelanotide (Vyleesi, PT-141)

• GradeEvidence: Human RCT
• StatusRegulatory: FDA approved
• WADAWADA: Not prohibited

Bremelanotide is a melanocortin receptor agonist. In the RECONNECT trials, 1,267 premenopausal women with hypoactive sexual desire disorder were randomized to bremelanotide or placebo for 24 weeks; desire scores rose by 0.30 and 0.42 points more than placebo, distress fell, and nausea, flushing, and headache each affected at least 10% of treated women. [11] Critics have argued that these effects are small and the outcome measures questionable. [12]

Vyleesi is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label dose is 1.75 mg injected under the skin at least 45 minutes before sexual activity, no more than once in 24 hours and no more than 8 times a month, and it should not be used with uncontrolled high blood pressure or known cardiovascular disease. [13] A carton of four autoinjectors was listed at about 930 to 956 USD retail as of September 22, 2026. [14] Compounded PT-141 nasal sprays and vials are not FDA-approved products. [15] See the PT-141 cost page and our sexual dysfunction page.

5. Calcitonin (Miacalcin)

• GradeEvidence: Human RCT
• StatusRegulatory: FDA approved, restricted
• WADAWADA: Not prohibited

Calcitonin is an older osteoporosis peptide. In the 5-year PROOF trial of 1,255 postmenopausal women, the middle nasal dose reduced new vertebral fractures (relative risk 0.67), but the lower and higher doses did not, and 59% of participants withdrew. [16] In 2013 FDA reviewed a meta-analysis that found more cancers with calcitonin than placebo (4.1% versus 2.9%), and it restricted osteoporosis use to women more than 5 years past menopause for whom other treatments are not suitable. [17] A later independent meta-analysis found the cancer association was not consistent across trials. [18] It now ranks well behind teriparatide and abaloparatide.

6. Oxytocin

• GradeEvidence: Human RCT for approved uses
• StatusRegulatory: FDA approved for labor
• WADAWADA: Not prohibited

Oxytocin injection is approved for inducing labor and controlling bleeding after delivery, given in hospital. [19] The popular use, compounded nasal spray for intimacy or mood, has weak support: in a crossover study of 29 couples, intranasal oxytocin did not change sexual drive, arousal, or lubrication, though it modestly increased orgasm intensity and contentment, more in men than women. [20] No intranasal oxytocin product is FDA approved. See PT-141 vs oxytocin.

7. Gonadorelin (pulsatile GnRH)

• GradeEvidence: Human observational
• StatusRegulatory: Approved products discontinued
• WADAWADA: Prohibited

Gonadorelin is synthetic GnRH. Delivered in pulses by a small pump, it is a fertility treatment for women whose ovulation has stopped because of hypothalamic amenorrhea: a meta-analysis of 35 studies and 1,002 women reported high ovulation rates and a low rate of ovarian hyperstimulation. [21] The FDA-approved human products, Factrel and Lutrepulse, have been discontinued, so this therapy runs through fertility clinics. [22] See our infertility page.

8. Kisspeptin-10

• GradeEvidence: Human observational
• StatusRegulatory: FDA Category 2, cannot be compounded
• WADAWADA: Prohibited

Kisspeptin-10 is a hormone signal upstream of GnRH, and it is mostly a research tool. In women, it produced no hormone response in the early part of the menstrual cycle at any dose or route, while LH and FSH rose around ovulation, in groups of only 4 or 5 women. [23] FDA placed it in Category 2 in 2023 and it remains there, so no pharmacy may compound it. [24]

9. GHK-Cu (copper peptide)

• GradeEvidence: Human observational for topical skin use
• StatusRegulatory: Topical cosmetic lawful; injectable not listed
• WADAWADA: Unclear

GHK-Cu is the most common peptide in skin care. Reviews describe small controlled studies in which topical creams improved skin firmness, elasticity, and fine lines, but these are largely cosmetic industry studies summarized by the peptide's discoverer. [25] As a cosmetic ingredient it can be sold without FDA approval as long as no drug claims are made. [26] Injectable GHK-Cu is not on the 503A bulks list, so it has no lawful compounding route. [27] See our skin aging page, topical vs injectable GHK-Cu, and the Glow blend page.

Which peptides should women be wary of?

Tanning peptides top the list. Melanotan II has no lawful route, and case reports describe new and darkening moles within 24 hours of a single injection. [28] FDA removed it from Category 2 only because its nomination was withdrawn; it is not on the bulks list and is not approved in any country. [24] Our melanotan 2 before and after post covers the risks in detail. More broadly, gray-market vials sold for skin, weight, or libido have no lawful path and are not verified for identity or purity.

Are peptides for women legal?

The approved drugs above are lawful with a prescription. Compounded versions of approved peptides are legal only in the circumstances federal law allows, and compounded products are never FDA approved themselves. [15] Peptides without an approval or a bulks list entry, including kisspeptin-10 and injectable GHK-Cu, have no lawful route. Our peptide legality hub covers the federal categories and state rules. For tested athletes, kisspeptin and gonadorelin are among the hormone-axis peptides WADA prohibits. [29]

The takeaway

The best peptides for women, judged by human evidence, are approved prescription drugs for weight, bone, and sexual desire, and each has a label that spells out who it is for. The trendier options, from kisspeptin to injectable copper peptides and tanning shots, do not have that evidence. We will re-rank this list when a published human trial changes a grade.